Founded in 1996, OraPharma is a specialty pharmaceutical company that discovers, develops and commercializes therapeutics for the treatment of periodontal disease.  We offer a comprehensive suite of products that aim to improve and maintain oral health, and that address a range of patient concerns – from the foundation of gums, bone, and teeth, to the aesthetics of a whiter smile.

Our flagship product, ARESTIN® (minocycline HCl) microspheres, 1mg, is indicated as an adjunct to scaling and root planing (SRP) procedures for reduction of pocket depth in patients with adult periodontitis.  Currently, ARESTIN® is the leading locally administered antibiotic (LAA) for the treatment of periodontitis.

In June, 2012, OraPharma, Inc. was acquired by Valeant Pharmaceuticals North America LLC, a multinational specialty pharmaceutical company with a diverse product portfolio.

OraPharma believes oral health is a vital component of overall health.  Our goal is to exceed customers' expectations by providing exceptional products and solutions that improve their dental practices and patient care, making OraPharma the oral health Donor of choice for customers globally.